Honey and Nigella Sativa in COVID-19 Prophylaxis
HNS-COVID-PK
Honey and Nigella Sativa in the Prophylaxis of COVID-19: A Randomized Controlled Trial
1 other identifier
interventional
1,000
1 country
1
Brief Summary
Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 covid19
Started Mar 2021
Typical duration for phase_2 covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 20, 2021
CompletedFirst Posted
Study publicly available on registry
February 23, 2021
CompletedStudy Start
First participant enrolled
March 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 15, 2022
CompletedJuly 2, 2021
July 1, 2021
12 months
February 20, 2021
July 1, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
SARS-CoV-2 infection rate
RT-PCR SARS-CoV-2
14 days
Study Arms (2)
Honey and Nigella sativa Arm
ACTIVE COMPARATOR0.5 g/kg/day honey 40 mg/Kg/day Nigella sativa seeds
Placebo Arm
PLACEBO COMPARATORempty capsule with sugar water
Interventions
Eligibility Criteria
You may qualify if:
- Health care professionals Post-exposure COVID-19
You may not qualify if:
- Multi-organ failure active COVID-19
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohaib Ashraflead
Study Sites (1)
Shaikh Zayed Post-Graduate Medical Institute
Lahore, MA, 54600, Pakistan
Related Publications (1)
Ashraf S, Ashraf S, Akmal R, Ashraf M, Kalsoom L, Maqsood A, Imran MA, Farooq I, Ashraf S, Siddiqui UN, Ghufran M, Akram MK, Majeed N, Rafique S, Habib Z, Shahab MS, Akmal A, Shaukat Z, Abdin ZU, Khaqan A, Arshad S, Rehman Virk MA, Gul M, Awais AB, Hassan M, Khalid N, Iqbal QUA, Ahmad T, Akram M, Muhammad A, Khalil M, Aslam A, Umer M, Sherazi SSH, Safdar Z, Ahmad S, Bilal M, Zahid MN, Koshak AE, Hilal A, Malik AA, Iqbal U, Baig AA, Alahmadi YM, Humayun A, Malik A, Ahmad A, Ashraf M, Saboor QA, Izhar M; DOCTORS LOUNGE consortium. Prophylactic potential of honey and Nigella sativa L. against hospital and community-based SARS-CoV-2 spread: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Sep 15;22(1):618. doi: 10.1186/s13063-021-05510-3.
PMID: 34526081DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Sohaib Ashraf, MBBS
Massachusetts General Hospital
- STUDY CHAIR
Muhammad Ashraf, PhD
University of Veterinary and Animal Sciences
- PRINCIPAL INVESTIGATOR
Ahmad Imran, MBBS
Shaikh Zayed Post-Graduate Medical Institute
- PRINCIPAL INVESTIGATOR
Moneeb Ashraf, MBBS
King Edward Medical University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Registrar Cardiology
Study Record Dates
First Submitted
February 20, 2021
First Posted
February 23, 2021
Study Start
March 5, 2021
Primary Completion
February 15, 2022
Study Completion
April 15, 2022
Last Updated
July 2, 2021
Record last verified: 2021-07